US20110082084A1 - Methods for the prevention or treatment of heart failure - Google Patents

Methods for the prevention or treatment of heart failure Download PDF

Info

Publication number
US20110082084A1
US20110082084A1 US12/897,325 US89732510A US2011082084A1 US 20110082084 A1 US20110082084 A1 US 20110082084A1 US 89732510 A US89732510 A US 89732510A US 2011082084 A1 US2011082084 A1 US 2011082084A1
Authority
US
United States
Prior art keywords
arg
phe
lys
peptide
dmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/897,325
Other languages
English (en)
Inventor
Hazel H. Szeto
Peter S. Rabinovitch
Dao-Fu Dai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Cornell University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/897,325 priority Critical patent/US20110082084A1/en
Application filed by Individual filed Critical Individual
Assigned to CORNELL UNIVERSITY reassignment CORNELL UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SZETO, HAZEL H.
Assigned to UNIVERSITY OF WASHINGTON reassignment UNIVERSITY OF WASHINGTON ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAI, DAO-FU, RABINOVITCH, PETER S.
Publication of US20110082084A1 publication Critical patent/US20110082084A1/en
Priority to US14/035,577 priority patent/US20140100166A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF WASHINGTON / CENTER FOR COMMERCIALIZATION
Priority to US14/727,513 priority patent/US20160106800A1/en
Priority to US15/723,259 priority patent/US20180236025A1/en
Priority to US16/796,940 priority patent/US11534476B2/en
Priority to US17/084,046 priority patent/US20210187056A1/en
Priority to US18/079,604 priority patent/US12102659B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Definitions

  • the present technology relates generally to compositions and methods of preventing or treating heart failure.
  • the present technology relates to administering aromatic-cationic peptides in effective amounts to prevent or treat heart failure in mammalian subjects.
  • Heart failure is a leading cause of mortality and morbidity worldwide. In the United States, it affects nearly 5 million people and is the only major cardiovascular disorder on the rise. It is estimated that 400,000 to 700,000 new cases of heart failure are diagnosed each year in the U.S. and the number of deaths in the U.S. attributable to this condition has more than doubled since 1979, currently averaging 250,000 annually. Although heart failure affects people of all ages, the risk of heart failure increases with age and is most common among older people. Accordingly, the number of people living with heart failure is expected to increase significantly as the elderly population grows over the next few decades.
  • the causes of heart failure have been linked to various disorders including coronary artery disease, past myocardial infarction, hypertension, abnormal heart valves, cardiomyopathy or myocarditis, congenital heart disease, severe lung disease, diabetes, severe anemia, hyperthyroidism, arrhythmia or dysrhythmia.
  • Heart failure also called congestive heart failure, is commonly characterized by decreased cardiac output, decreased cardiac contractility, abnormal diastolic compliance, reduced stroke volume, and pulmonary congestion.
  • the clinical manifestations of heart failure reflect a decrease in the myocardial contractile state and a reduction in cardiac output.
  • the HF disease state may arise from left ventricular failure, right ventricular failure, biventricular failure, systolic dysfunction, diastolic dysfunction, and pulmonary effects.
  • a progressive decrease in the contractile function of cardiac muscle, associated with heart disease often leads to hypoperfusion of critical organs.
  • the present technology relates generally to the treatment or prevention of heart failure in mammals through administration of therapeutically effective amounts of aromatic-cationic peptides to subjects in need thereof.
  • the aromatic-cationic peptides treat or prevent heart failure by enhancing mitochondrial function in cardiac tissues.
  • the disclosure provides a method of treating or preventing heart failure or hypertensive cardiomyopathy, comprising administering to said mammalian subject a therapeutically effective amount of an aromatic-cationic peptide.
  • the aromatic-cationic peptide is a peptide having:
  • the mammalian subject is a human.
  • 2p m is the largest number that is less than or equal to r+1, and a may be equal to p t .
  • the aromatic-cationic peptide may be a water-soluble peptide having a minimum of two or a minimum of three positive charges.
  • the peptide comprises one or more non-naturally occurring amino acids, for example, one or more D-amino acids.
  • the C-terminal carboxyl group of the amino acid at the C-terminus is amidated.
  • the peptide has a minimum of four amino acids. The peptide may have a maximum of about 6, a maximum of about 9, or a maximum of about 12 amino acids.
  • the peptide comprises a tyrosine or a 2′,6′-dimethyltyrosine (Dmt) residue at the N-terminus.
  • the peptide may have the formula Tyr-D-Arg-Phe-Lys-NH 2 (SS-01) or 2′,6′-Dmt-D-Arg-Phe-Lys-NH 2 (SS-02).
  • the peptide comprises a phenylalanine or a 2′,6′-dimethylphenylalanine residue at the N-terminus.
  • the peptide may have the formula Phe-D-Arg-Phe-Lys-NH 2 (SS-20) or 2′,6′-Dmp-D-Arg-Phe-Lys-NH 2 .
  • the aromatic-cationic peptide has the formula D-Arg-2′,6′-Dmt-Lys-Phe-NH 2 (referred to interchangeably as SS-31, MTP-131, or BendaviaTM)
  • the peptide is defined by formula I:
  • R 1 and R 2 are each independently selected from
  • R 3 and R 4 are each independently selected from
  • halogen encompasses chloro, fluoro, bromo, and iodo
  • R 5 , R 6 , R 7 , R 8 , and R 9 are each independently selected from
  • halogen encompasses chloro, fluoro, bromo, and iodo; and n is an integer from 1 to 5.
  • R 1 and R 2 are hydrogen; R 3 and R 4 are methyl; R 5 , R 6 , R 7 , R 8 , and R 9 are all hydrogen; and n is 4.
  • the peptide is defined by formula II:
  • R 1 and R 2 are each independently selected from
  • R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are each independently selected from
  • halogen encompasses chloro, fluoro, bromo, and iodo; and n is an integer from 1 to 5.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 R 9 , R 10 , R 11 , and R 12 are all hydrogen; and n is 4.
  • R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , and R 11 are all hydrogen; R 8 and R 12 are methyl; R 10 is hydroxyl; and n is 4.
  • the subject is suffering from heart failure.
  • the heart failure results from hypertension; ischemic heart disease; exposure to a cardiotoxic compound; myocarditis; thyroid disease; viral infection; gingivitis; drug abuse; alcohol abuse; pericarditis; atherosclerosis; vascular disease; hypertrophic cardiomyopathy; acute myocardial infarction; left ventricular systolic dysfunction; coronary bypass surgery; starvation; an eating disorder; or a genetic defect.
  • the subject is suffering hypertensive cardiomyopathy.
  • myocardial contractility and cardiac output in the subject administered the peptide are increased compared to a control subject not administered the peptide. In one embodiment, the myocardial contractility and cardiac output in the subject are increased at least 10% compared to a control subject not administered the peptide.
  • the method further comprises separately, sequentially or simultaneously administering a cardiovascular agent to the subject.
  • the cardiovascular agent is selected from the group consisting of: an anti-arrhthymia agent, a vasodilator, an anti-anginal agent, a corticosteroid, a cardioglycoside, a diuretic, a sedative, an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II antagonist, a thrombolytic agent, a calcium channel blocker, a throboxane receptor antagonist, a radical scavenger, an anti-platelet drug, a ⁇ -adrenaline receptor blocking drug, ⁇ -receptor blocking drug, a sympathetic nerve inhibitor, a digitalis formulation, an inotrope, and an antihyperlipidemic drug.
  • ACE angiotensin converting enzyme
  • the disclosure provides a method for increasing myocardial contractility and cardiac output in a subject suffering from heart failure or hypertensive cardiomyopathy comprising administering to the subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH 2 or Phe-D-Arg-Phe-Lys-NH 2 .
  • the aromatic-cationic peptides may be administered in a variety of ways.
  • the peptides may be administered orally, topically, intranasally, intraperitoneally, intravenously, subcutaneously, or transdermally (e.g., by iontophoresis).
  • FIG. 1 is a graph of flow cytometric analysis of neonatal cardiomyocytes stimulated with Ang II (1 ⁇ M) and loaded with Mitosox (5 ⁇ M), an indicator of mitochondrial ROS.
  • FIG. 2 is a series of charts showing the effects of SS-31 on blood pressure after a pressor dose of Ang II.
  • FIG. 2A Representative blood pressure tracings of mice at baseline and after Ang II (1.1 mg/kg/d) administered with a subcutaneous pump.
  • FIG. 2B Ang II significantly increased systolic blood pressure by 27.2 mm Hg and diastolic pressure by 24.8 mm Hg.
  • FIG. 3 is a series of charts showing that SS-31 ameliorates Ang-II-induced cardiac hypertrophy and diastolic dysfunction.
  • FIG. 3A Ang II (1.1 mg/kg/d) for 4 weeks substantially increased LVMI in WT control mice. Simultaneous administration of SS-31 (3 mg/kg/d) significantly attenuated the Ang II-induced increase in LVMI (left panel), to a similar extent as that observed in mice with inducible overexpression of mitochondrial catalase (i-mCAT, right panel).
  • FIG. 3C Left ventricular end-diastolic diameter (LVEDD) and fractional shortening (FS,%) were not significantly changed after 4 weeks of Ang II in the presence or absence of mitochondrial antioxidants.
  • FIG. 3D Diastolic function measured by tissue Doppler imaging of Ea/Aa significantly reduced after 4 weeks of Ang II, but this is significantly ameliorated by SS-31 or genetic overexpression of mCAT.
  • FIG. 4 is a series of charts showing SS-31 attenuates Ang-II induced cardiac hypertrophy and fibrosis.
  • FIG. 4A Ang II significantly increased heart weight (normalized to tibia length) and this was significantly attenuated by SS-31.
  • FIG. 4B Quantitative PCR showed a dramatic increase in atrial natriuretic peptide (ANP) gene expression, which was significantly prevented by SS-31.
  • FIG. 4C Representative histopathology shows substantial perivascular fibrosis (PVF) and interstitial fibrosis (IF) after Ang II, which was better protected in SS-31 treated hearts.
  • FIG. 4A Ang II significantly increased heart weight (normalized to tibia length) and this was significantly attenuated by SS-31.
  • FIG. 4B Quantitative PCR showed a dramatic increase in atrial natriuretic peptide (ANP) gene expression, which was significantly prevented by SS-31.
  • FIG. 4D Quantitative analysis of blue trichrome staining demonstrated a significant increase in ventricular fibrosis after Ang II, and this was substantially attenuated by SS-31.
  • FIG. 4E Quantitative PCR showed upregulation of pro-collagen 1a2 mRNA after Ang II, which was significantly reduced in SS-31 hearts.
  • FIG. 5 is a series of charts showing mitochondrial protein carbonyl and signaling for mitochondrial biogenesis increased after 4 weeks of Ang II treatment, which was prevented by SS-31.
  • FIG. 5A Ang II for 4 weeks significantly increased cardiac mitochondrial protein carbonyl content, an indicator of protein oxidative damage, and this was significantly ameliorated by SS-31.
  • FIG. 5B Quantitative PCR revealed significant upregulation of genes in mitochondrial biogenesis, all of which were attenuated by SS-31. *p ⁇ 0.05 compared with saline group, #p ⁇ 0.05 compared with Ang II treated group.
  • FIG. 6 is a series of charts showing SS-31 acts downstream of NADPH oxidase and reduces activation of p38 MAPK and apoptosis in response to Ang II.
  • FIG. 6A NADPH oxidase activity was significantly increased after Ang II. No significant effect of SS-31 was observed.
  • FIG. 6B Ang II for 4 weeks substantially induced apoptosis, as shown by increase in cleaved (activated) caspase 3 and this was significantly attenuated by SS-31.
  • FIG. 6C Phosphorylation of p38 MAP kinase significantly increased after Ang II, which was substantially lower in SS-31 treated hearts (upper panel). Protein levels of p38 MAP kinase also increased after Ang II.
  • FIG. 7 is a series of charts showing SS-31 ameliorated cardiac hypertrophy and failure in G ⁇ q overexpressing mice. Echocardiography of G ⁇ q mice with or without SS-31 treatment and WT littermates at 16 weeks of age.
  • FIG. 7A SS-31 (3 mg/kg/d) for 4 weeks (from age 12 to 16 weeks) significantly ameliorated the decline in systolic function, as indicated by FS, in G ⁇ q overexpressing mice.
  • FIG. 7 is a series of charts showing SS-31 ameliorated cardiac hypertrophy and failure in G ⁇ q overexpressing mice. Echocardiography of G ⁇ q mice with or without SS-31 treatment and WT littermates at 16 weeks of age.
  • FIG. 7A SS-31 (3 mg/kg/d) for 4 weeks (from age 12 to 16
  • FIG. 7D Worsening of myocardial performance index (MPI) in G ⁇ q mice was significantly ameliorated by SS-31.
  • FIG. 8 is a diagrammatic illustration of the proposed effect of mitochondrial antioxidant SS-31 on Ang II and G ⁇ q-induced cardiomyopathy.
  • Mitochondrial antioxidant SS-31 acts downstream to Angiotensin II receptor, G ⁇ q, NADPH oxidase and upstream of p38 MAPK and apoptosis.
  • FIG. 9 is a series of charts showing both cardiac fibrosis and cardiac expression of Coll 1a2 gene were not significantly altered by 4 weeks of SS-31 treatment ( FIG. 9A and FIG. 9B ).
  • FIG. 9C shows cardiac mitochondrial protein carbonyl content significantly increased after Ang II, which was reduced by SS-31.
  • the “administration” of an agent, drug, or peptide to a subject includes any route of introducing or delivering to a subject a compound to perform its intended function. Administration can be carried out by any suitable route, including orally, intranasally, parenterally (intravenously, intramuscularly, intraperitoneally, or subcutaneously), or topically. Administration includes self-administration and the administration by another.
  • amino acid includes naturally-occurring amino acids and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally-occurring amino acids.
  • Naturally-occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ⁇ -carboxyglutamate, and O-phosphoserine.
  • Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally-occurring amino acid, i.e., an ⁇ -carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium.
  • Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally-occurring amino acid.
  • Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally-occurring amino acid. Amino acids can be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission.
  • the term “effective amount” refers to a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect, e.g., an amount which results in the prevention of, or a decrease in, heart failure or one or more symptoms associated with heart failure.
  • the amount of a composition administered to the subject will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
  • the compositions can also be administered in combination with one or more additional therapeutic compounds.
  • the aromatic-cationic peptides may be administered to a subject having one or more signs or symptoms of heart failure, such as cardiomegaly, tachypnea, and hepatomegaly.
  • a “therapeutically effective amount” of the aromatic-cationic peptides is meant levels in which the physiological effects of a heart failure are, at a minimum, ameliorated.
  • CHF congestive heart failure
  • chronic heart failure chronic heart failure
  • acute heart failure acute heart failure
  • heart failure refers to any condition characterized by abnormally low cardiac output in which the heart is unable to pump blood at an adequate rate or in adequate volume.
  • Typical symptoms of heart failure include shortness of breath (dyspnea), fatigue, weakness, difficulty breathing when lying flat, and swelling of the legs, ankles or abdomen (edema).
  • causes of heart failure are related to various disorders including coronary artery disease, systemic hypertension, cardiomyopathy or myocarditis, congenital heart disease, abnormal heart valves or valvular heart disease, severe lung disease, diabetes, severe anemia hyperthyroidism, arrhythmia or dysrhythmia and myocardial infarction.
  • the primary signs of congestive heart failure are: cardiomegaly (enlarged heart), tachypnea (rapid breathing; occurs in the case of left side failure) and hepatomegaly (enlarged liver; occurs in the case of right side failure).
  • hypertensive cardiomyopathy refers to a weakened heart caused by the effects of hypertension (high blood pressure). Over time, uncontrolled hypertension causes weakness of the heart muscle. As hypertensive cardiomyopathy worsens, it can lead to congestive heart failure. Early symptoms of hypertensive cardiomyopathy include cough, weakness, and fatigue. Additional symptoms of hypertensive cardiomyopathy include leg swelling, weight gain, difficulty breathing when lying flat, increasing shortness of breath with activity, and waking in the middle of the night short of breath.
  • an “isolated” or “purified” polypeptide or peptide is substantially free of cellular material or other contaminating polypeptides from the cell or tissue source from which the agent is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized.
  • an isolated aromatic-cationic peptide would be free of materials that would interfere with diagnostic or therapeutic uses of the agent.
  • interfering materials may include enzymes, hormones and other proteinaceous and nonproteinaceous solutes.
  • polypeptide As used herein, the terms “polypeptide”, “peptide”, and “protein” are used interchangeably herein to mean a polymer comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.
  • Polypeptide refers to both short chains, commonly referred to as peptides, glycopeptides or oligomers, and to longer chains, generally referred to as proteins.
  • Polypeptides may contain amino acids other than the 20 gene-encoded amino acids.
  • Polypeptides include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art.
  • the term “simultaneous” therapeutic use refers to the administration of at least two active ingredients by the same route and at the same time or at substantially the same time.
  • the term “separate” therapeutic use refers to an administration of at least two active ingredients at the same time or at substantially the same time by different routes.
  • sequential therapeutic use refers to administration of at least two active ingredients at different times, the administration route being identical or different. More particularly, sequential use refers to the whole administration of one of the active ingredients before administration of the other or others commences. It is thus possible to administer one of the active ingredients over several minutes, hours, or days before administering the other active ingredient or ingredients. There is no simultaneous treatment in this case.
  • the terms “treating” or “treatment” or “alleviation” refers to therapeutic treatment, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder.
  • a subject is successfully “treated” for heart failure if, after receiving a therapeutic amount of the aromatic-cationic peptides according to the methods described herein, the subject shows observable and/or measurable reduction in or absence of one or more signs and symptoms of heart failure, such as, e.g., cardiac output, myocardial contractile force, cardiomegaly, tachonea, and/or hepahemogaly.
  • Treating heart failure also refers to treating any one or more of the conditions underlying heart failure, including, without limitation, decreased cardiac contractility, abnormal diastolic compliance, reduced stroke volume, pulmonary congestion, and decreased cardiac output.
  • prevention or “preventing” of a disorder or condition refers to a compound that, in a statistical sample, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated control sample.
  • preventing heart failure includes preventing the initiation of heart failure, delaying the initiation of heart failure, preventing the progression or advancement of heart failure, slowing the progression or advancement of heart failure, delaying the progression or advancement of heart failure, and reversing the progression of heart failure from an advanced to a less advanced stage.
  • the present technology relates to the treatment or prevention of heart failure and related conditions by administration of certain aromatic-cationic peptides.
  • the aromatic-cationic peptides are water-soluble and highly polar. Despite these properties, the peptides can readily penetrate cell membranes.
  • the aromatic-cationic peptides typically include a minimum of three amino acids or a minimum of four amino acids, covalently joined by peptide bonds.
  • the maximum number of amino acids present in the aromatic-cationic peptides is about twenty amino acids covalently joined by peptide bonds.
  • the maximum number of amino acids is about twelve, more preferably about nine, and most preferably about six.
  • amino acids of the aromatic-cationic peptides can be any amino acid.
  • amino acid is used to refer to any organic molecule that contains at least one amino group and at least one carboxyl group. Typically, at least one amino group is at the a position relative to a carboxyl group.
  • the amino acids may be naturally occurring.
  • Naturally occurring amino acids include, for example, the twenty most common levorotatory (L) amino acids normally found in mammalian proteins, i.e., alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan, (Trp), tyrosine (Tyr), and valine (Val).
  • L levorotatory
  • Naturally occurring amino acids include, for example, amino acids that are synthesized in metabolic processes not associated with protein synthesis.
  • amino acids ornithine and citrulline are synthesized in mammalian metabolism during the production of urea.
  • Another example of a naturally occurring amino acid includes hydroxyproline (Hyp).
  • the peptides optionally contain one or more non-naturally occurring amino acids.
  • the peptide has no amino acids that are naturally occurring.
  • the non-naturally occurring amino acids may be levorotary (L-), dextrorotatory (D-), or mixtures thereof.
  • Non-naturally occurring amino acids are those amino acids that typically are not synthesized in normal metabolic processes in living organisms, and do not naturally occur in proteins.
  • the non-naturally occurring amino acids suitably are also not recognized by common proteases.
  • the non-naturally occurring amino acid can be present at any position in the peptide.
  • the non-naturally occurring amino acid can be at the N-terminus, the C-terminus, or at any position between the N-terminus and the C-terminus.
  • the non-natural amino acids may, for example, comprise alkyl, aryl, or alkylaryl groups not found in natural amino acids.
  • Some examples of non-natural alkyl amino acids include ⁇ -aminobutyric acid, ⁇ -aminobutyric acid, ⁇ -aminobutyric acid, ⁇ -aminovaleric acid, and ⁇ -aminocaproic acid.
  • Some examples of non-natural aryl amino acids include ortho-, meta, and para-aminobenzoic acid.
  • Some examples of non-natural alkylaryl amino acids include ortho-, meta-, and para-aminophenylacetic acid, and ⁇ -phenyl- ⁇ -aminobutyric acid.
  • Non-naturally occurring amino acids include derivatives of naturally occurring amino acids.
  • the derivatives of naturally occurring amino acids may, for example, include the addition of one or more chemical groups to the naturally occurring amino acid.
  • one or more chemical groups can be added to one or more of the 2′, 3′, 4′, 5′, or 6′ position of the aromatic ring of a phenylalanine or tyrosine residue, or the 4′, 5′, 6′, or 7′ position of the benzo ring of a tryptophan residue.
  • the group can be any chemical group that can be added to an aromatic ring.
  • Some examples of such groups include branched or unbranched C 1 -C 4 alkyl, such as methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, or t-butyl, C 1 -C 4 alkyloxy (i.e., alkoxy), amino, C 1 -C 4 alkylamino and C 1 -C 4 dialkylamino (e.g., methylamino, dimethylamino), nitro, hydroxyl, halo (i.e., fluoro, chloro, bromo, or iodo).
  • Some specific examples of non-naturally occurring derivatives of naturally occurring amino acids include norvaline (Nva) and norleucine (Nle).
  • Another example of a modification of an amino acid in a peptide is the derivatization of a carboxyl group of an aspartic acid or a glutamic acid residue of the peptide.
  • derivatization is amidation with ammonia or with a primary or secondary amine, e.g. methylamine, ethylamine, dimethylamine or diethylamine.
  • Another example of derivatization includes esterification with, for example, methyl or ethyl alcohol.
  • Another such modification includes derivatization of an amino group of a lysine, arginine, or histidine residue.
  • amino groups can be acylated.
  • Some suitable acyl groups include, for example, a benzoyl group or an alkanoyl group comprising any of the C 1 -C 4 alkyl groups mentioned above, such as an acetyl or propionyl group.
  • the non-naturally occurring amino acids are suitably resistant or insensitive to common proteases.
  • non-naturally occurring amino acids that are resistant or insensitive to proteases include the dextrorotatory (D-) form of any of the above-mentioned naturally occurring L-amino acids, as well as L- and/or D-non-naturally occurring amino acids.
  • D-amino acids do not normally occur in proteins, although they are found in certain peptide antibiotics that are synthesized by means other than the normal ribosomal protein synthetic machinery of the cell. As used herein, the D-amino acids are considered to be non-naturally occurring amino acids.
  • the peptides should have less than five, preferably less than four, more preferably less than three, and most preferably, less than two contiguous L-amino acids recognized by common proteases, irrespective of whether the amino acids are naturally or non-naturally occurring.
  • the peptide has only D-amino acids, and no L-amino acids. If the peptide contains protease sensitive sequences of amino acids, at least one of the amino acids is preferably a non-naturally-occurring D-amino acid, thereby conferring protease resistance.
  • protease sensitive sequence includes two or more contiguous basic amino acids that are readily cleaved by common proteases, such as endopeptidases and trypsin.
  • basic amino acids include arginine, lysine and histidine.
  • the aromatic-cationic peptides should have a minimum number of net positive charges at physiological pH in comparison to the total number of amino acid residues in the peptide.
  • the minimum number of net positive charges at physiological pH will be referred to below as (p m ).
  • the total number of amino acid residues in the peptide will be referred to below as (r).
  • the minimum number of net positive charges discussed below are all at physiological pH.
  • physiological pH refers to the normal pH in the cells of the tissues and organs of the mammalian body. For instance, the physiological pH of a human is normally approximately 7.4, but normal physiological pH in mammals may be any pH from about 7.0 to about 7.8.
  • Net charge refers to the balance of the number of positive charges and the number of negative charges carried by the amino acids present in the peptide. In this specification, it is understood that net charges are measured at physiological pH.
  • the naturally occurring amino acids that are positively charged at physiological pH include L-lysine, L-arginine, and L-histidine.
  • the naturally occurring amino acids that are negatively charged at physiological pH include L-aspartic acid and L-glutamic acid.
  • a peptide typically has a positively charged N-terminal amino group and a negatively charged C-terminal carboxyl group. The charges cancel each other out at physiological pH.
  • the peptide Tyr-Arg-Phe-Lys-Glu-His-Trp-D-Arg has one negatively charged amino acid (i.e., Glu) and four positively charged amino acids (i.e., two Arg residues, one Lys, and one His). Therefore, the above peptide has a net positive charge of three.
  • the aromatic-cationic peptides have a relationship between the minimum number of net positive charges at physiological pH (p m ) and the total number of amino acid residues (r) wherein 3p m is the largest number that is less than or equal to r+1.
  • the relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) is as follows:
  • the aromatic-cationic peptides have a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 2p m is the largest number that is less than or equal to r+1.
  • the relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) is as follows:
  • the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) are equal.
  • the peptides have three or four amino acid residues and a minimum of one net positive charge, suitably, a minimum of two net positive charges and more preferably a minimum of three net positive charges.
  • aromatic-cationic peptides have a minimum number of aromatic groups in comparison to the total number of net positive charges (p t ).
  • the minimum number of aromatic groups will be referred to below as (a).
  • Naturally occurring amino acids that have an aromatic group include the amino acids histidine, tryptophan, tyrosine, and phenylalanine.
  • the hexapeptide Lys-Gln-Tyr-D-Arg-Phe-Trp has a net positive charge of two (contributed by the lysine and arginine residues) and three aromatic groups (contributed by tyrosine, phenylalanine and tryptophan residues).
  • the aromatic-cationic peptides should also have a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges at physiological pH (p t ) wherein 3a is the largest number that is less than or equal to p t +1, except that when p t is 1, a may also be 1.
  • the relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) is as follows:
  • the aromatic-cationic peptides have a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2a is the largest number that is less than or equal to p t +1.
  • the relationship between the minimum number of aromatic amino acid residues (a) and the total number of net positive charges (p t ) is as follows:
  • the number of aromatic groups (a) and the total number of net positive charges (p t ) are equal.
  • Carboxyl groups are suitably amidated with, for example, ammonia to form the C-terminal amide.
  • the terminal carboxyl group of the C-terminal amino acid may be amidated with any primary or secondary amine.
  • the primary or secondary amine may, for example, be an alkyl, especially a branched or unbranched C 1 -C 4 alkyl, or an aryl amine.
  • the amino acid at the C-terminus of the peptide may be converted to an amido, N-methylamido, N-ethylamido, N,N-dimethylamido, N,N-diethylamido, N-methyl-N-ethylamido, N-phenylamido or N-phenyl-N-ethylamido group.
  • the free carboxylate groups of the asparagine, glutamine, aspartic acid, and glutamic acid residues not occurring at the C-terminus of the aromatic-cationic peptides may also be amidated wherever they occur within the peptide.
  • the amidation at these internal positions may be with ammonia or any of the primary or secondary amines described above.
  • the aromatic-cationic peptide is a tripeptide having two net positive charges and at least one aromatic amino acid. In a particular embodiment, the aromatic-cationic peptide is a tripeptide having two net positive charges and two aromatic amino acids.
  • Aromatic-cationic peptides include, but are not limited to, the following peptide examples:
  • the peptides have mu-opioid receptor agonist activity (i.e., they activate the mu-opioid receptor).
  • Peptides which have mu-opioid receptor agonist activity are typically those peptides which have a tyrosine residue or a tyrosine derivative at the N-terminus (i.e., the first amino acid position).
  • Suitable derivatives of tyrosine include 2′-methyltyrosine (Mmt); 2′,6′-dimethyltyrosine (2′6′-Dmt); 3′,5′-dimethyltyrosine (3′5′Dmt); N,2′,6′-trimethyltyrosine (Tmt); and 2′-hydroxy-6′-methyltryosine (Hmt).
  • a peptide that has mu-opioid receptor agonist activity has the formula Tyr-D-Arg-Phe-Lys-NH 2 (referred to herein as “SS-01”).
  • SS-01 has a net positive charge of three, contributed by the amino acids tyrosine, arginine, and lysine and has two aromatic groups contributed by the amino acids phenylalanine and tyrosine.
  • the tyrosine of SS-01 can be a modified derivative of tyrosine such as in 2′,6′-dimethyltyrosine to produce the compound having the formula 2′,6′-Dmt-D-Arg-Phe-Lys-NH 2 (referred to herein as “SS-02”).
  • SS-02 has a molecular weight of 640 and carries a net three positive charge at physiological pH. SS-02 readily penetrates the plasma membrane of several mammalian cell types in an energy-independent manner (Zhao et al., J. Pharmacol Exp Ther., 304:425-432, 2003).
  • the aromatic-cationic peptide does not have mu-opioid receptor agonist activity.
  • the use of an aromatic-cationic peptide that activates the mu-opioid receptor may be contraindicated.
  • the potentially adverse or addictive effects of the aromatic-cationic peptide may preclude the use of an aromatic-cationic peptide that activates the mu-opioid receptor in the treatment regimen of a human patient or other mammal. Potential adverse effects may include sedation, constipation and respiratory depression.
  • an aromatic-cationic peptide that does not activate the mu-opioid receptor may be an appropriate treatment.
  • Peptides that do not have mu-opioid receptor agonist activity generally do not have a tyrosine residue or a derivative of tyrosine at the N-terminus (i.e., amino acid position 1).
  • the amino acid at the N-terminus can be any naturally occurring or non-naturally occurring amino acid other than tyrosine.
  • the amino acid at the N-terminus is phenylalanine or its derivative.
  • exemplary derivatives of phenylalanine include 2′-methylphenylalanine (Mmp), 2′,6′-dimethylphenylalanine (2′,6′-Dmp), N,2′,6′-trimethylphenylalanine (Tmp), and 2′-hydroxy-6′-methylphenylalanine (Hmp).
  • an aromatic-cationic peptide that does not have mu-opioid receptor agonist activity has the formula Phe-D-Arg-Phe-Lys-NH 2 (referred to herein as “SS-20”).
  • the N-terminal phenylalanine can be a derivative of phenylalanine such as 2′,6′-dimethylphenylalanine (2′,6′-Dmp).
  • SS-01 containing 2′,6′-dimethylphenylalanine at amino acid position 1 has the formula 2′,6′-Dmp-D-Arg-Phe-Lys-NH 2 .
  • the amino acid sequence of SS-02 is rearranged such that Dmt is not at the N-terminus.
  • An example of such an aromatic-cationic peptide that does not have mu-opioid receptor agonist activity has the formula D-Arg-2′6′-Dmt-Lys-Phe-NH 2 .
  • Suitable substitution variants of the peptides listed herein include conservative amino acid substitutions.
  • Amino acids may be grouped according to their physicochemical characteristics as follows:
  • Non-polar amino acids Ala(A) Ser(S) Thr(T) Pro(P) Gly(G) Cys(C);
  • H is(H) Arg(R) Lys(K);
  • Aromatic amino acids Phe(F) Tyr(Y) Trp(W) His(H).
  • substitutions of an amino acid in a peptide by another amino acid in the same group is referred to as a conservative substitution and may preserve the physicochemical characteristics of the original peptide.
  • substitutions of an amino acid in a peptide by another amino acid in a different group is generally more likely to alter the characteristics of the original peptide.
  • peptides that activate mu-opioid receptors include, but are not limited to, the aromatic-cationic peptides shown in Table 5.
  • peptides that do not activate mu-opioid receptors include, but are not limited to, the aromatic-cationic peptides shown in Table 6.
  • amino acids of the peptides shown in Table 5 and 6 may be in either the L- or the D-configuration.
  • the peptides may be synthesized by any of the methods well known in the art. Suitable methods for chemically synthesizing the protein include, for example, those described by Stuart and Young in Solid Phase Peptide Synthesis , Second Edition, Pierce Chemical Company (1984), and in Methods Enzymol., 289, Academic Press, Inc, New York (1997).
  • the aromatic-cationic peptides described herein are useful to prevent or treat disease.
  • the disclosure provides for both prophylactic and therapeutic methods of treating a subject having or at risk of (susceptible to) heart failure.
  • the present methods provide for the prevention and/or treatment of heart failure in a subject by administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. See Tsutsui et al. “Mitochondrial oxidative stress, DNA damage, and heart failure.” Antioxidants and Redox Signaling. 8(9): 1737-1744 (2006).
  • compositions or medicaments are administered to a subject suspected of, or already suffering from such a disease in an amount sufficient to cure, or at least partially arrest, the symptoms of the disease, including its complications and intermediate pathological phenotypes in development of the disease.
  • the invention provides methods of treating an individual afflicted with heart failure.
  • Subjects suffering from heart failure can be identified by any or a combination of diagnostic or prognostic assays known in the art.
  • typical symptoms of heart failure include shortness of breath (dyspnea), fatigue, weakness, difficulty breathing when lying flat, and swelling of the legs, ankles or abdomen (edema).
  • the subject may also be suffering from other disorders including coronary artery disease, systemic hypertension, cardiomyopathy or myocarditis, congenital heart disease, abnormal heart valves or valvular heart disease, severe lung disease, diabetes, severe anemia hyperthyroidism, arrhythmia or dysrhythmia and myocardial infarction.
  • AMI Acute myocardial infarction
  • the present disclosure provides a method of treating hypertensive cardiomyopathy by administering an effective amount of an aromatic-cationic peptide to a subject in need thereof.
  • hypertensive cardiomyopathy worsens, it can lead to congestive heart failure.
  • Subjects suffering from hypertensive cardiomyopathy can be identified by any or a combination of diagnostic or prognostic assays known in the art.
  • typical symptoms of hypertensive cardiomyopathy include hypertension (high blood pressure), cough, weakness, and fatigue.
  • Additional symptoms of hypertensive cardiomyopathy include leg swelling, weight gain, difficulty breathing when lying flat, increasing shortness of breath with activity, and waking in the middle of the night short of breath.
  • the invention provides a method for preventing, in a subject, heart failure by administering to the subject an aromatic-cationic peptide that prevents the initiation or progression of the infection.
  • Subjects at risk for heart failure can be identified by, e.g., any or a combination of diagnostic or prognostic assays as described herein.
  • pharmaceutical compositions or medicaments of aromatic-cationic peptides are administered to a subject susceptible to, or otherwise at risk of a disease or condition in an amount sufficient to eliminate or reduce the risk, lessen the severity, or delay the outset of the disease, including biochemical, histologic and/or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting during development of the disease.
  • Administration of a prophylactic aromatic-cationic can occur prior to the manifestation of symptoms characteristic of the aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression.
  • the appropriate compound can be determined based on screening assays described above.
  • suitable in vitro or in vivo assays are performed to determine the effect of a specific aromatic-cationic peptide-based therapeutic and whether its administration is indicated for treatment.
  • in vitro assays can be performed with representative animal models, to determine if a given aromatic-cationic peptide-based therapeutic exerts the desired effect in preventing or treating heart failure.
  • Compounds for use in therapy can be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art can be used prior to administration to human subjects.
  • HF has been induced in different species with volume overload, pressure overload, fast pacing, myocardial ischemia, cardiotoxic drugs, or genetically modified models. Models using pressure overload have been most commonly used. Hypertension is associated with an increased risk for the development of HF.
  • angiotensin II Ang II
  • Ang II increases blood pressure and induces cardiomyocyte hypertrophy, increased cardiac fibrosis, and impaired cardiomyocyte relaxation.
  • Infusion of angiotensin to mice by mini osmotic pump increases systolic and diastolic blood pressure, increases heart weight and left ventricular thickness (LVMI), and impaired myocardial performance index (MPI).
  • G ⁇ q ⁇ -adrenergic receptors
  • ⁇ ARs ⁇ -adrenergic receptors
  • Gs heterotrimeric G protein
  • This association generates intracellular cAMP and protein kinase A activation, which regulate cardiac contractility and heart rate.
  • Overexpression of G ⁇ q leads to decreased responsiveness to ⁇ -adrenergic agonists and results in HF.
  • TAC Transaortic constriction
  • LV left ventricular
  • any method known to those in the art for contacting a cell, organ or tissue with a peptide may be employed. Suitable methods include in vitro, ex vivo, or in vivo methods. In vivo methods typically include the administration of an aromatic-cationic peptide, such as those described above, to a mammal, suitably a human. When used in vivo for therapy, the aromatic-cationic peptides are administered to the subject in effective amounts (i.e., amounts that have desired therapeutic effect). The dose and dosage regimen will depend upon the degree of the infection in the subject, the characteristics of the particular aromatic-cationic peptide used, e.g., its therapeutic index, the subject, and the subject's history.
  • the effective amount may be determined during pre-clinical trials and clinical trials by methods familiar to physicians and clinicians.
  • An effective amount of a peptide useful in the methods may be administered to a mammal in need thereof by any of a number of well-known methods for administering pharmaceutical compounds.
  • the peptide may be administered systemically or locally.
  • the peptide may be formulated as a pharmaceutically acceptable salt.
  • pharmaceutically acceptable salt means a salt prepared from a base or an acid which is acceptable for administration to a patient, such as a mammal (e.g., salts having acceptable mammalian safety for a given dosage regime). However, it is understood that the salts are not required to be pharmaceutically acceptable salts, such as salts of intermediate compounds that are not intended for administration to a patient.
  • Pharmaceutically acceptable salts can be derived from pharmaceutically acceptable inorganic or organic bases and from pharmaceutically acceptable inorganic or organic acids.
  • salts derived from pharmaceutically acceptable inorganic bases include ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, and zinc salts, and the like.
  • Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperadine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
  • arginine betaine
  • caffeine choline
  • Salts derived from pharmaceutically acceptable inorganic acids include salts of boric, carbonic, hydrohalic (hydrobromic, hydrochloric, hydrofluoric or hydroiodic), nitric, phosphoric, sulfamic and sulfuric acids.
  • Salts derived from pharmaceutically acceptable organic acids include salts of aliphatic hydroxyl acids (e.g., citric, gluconic, glycolic, lactic, lactobionic, malic, and tartaric acids), aliphatic monocarboxylic acids (e.g., acetic, butyric, formic, propionic and trifluoroacetic acids), amino acids (e.g., aspartic and glutamic acids), aromatic carboxylic acids (e.g., benzoic, p-chlorobenzoic, diphenylacetic, gentisic, hippuric, and triphenylacetic acids), aromatic hydroxyl acids (e.g., o-hydroxybenzoic, p-hydroxybenzoic, 1-hydroxynaphthalene-2-carboxylic and 3-hydroxynaphthalene-2-carboxylic acids), ascorbic, dicarboxylic acids (e.g., fumaric, maleic, oxalic and succinic acids), glucuronic
  • compositions for administration, singly or in combination, to a subject for the treatment or prevention of a disorder described herein.
  • Such compositions typically include the active agent and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
  • Supplementary active compounds can also be incorporated into the compositions.
  • compositions are typically formulated to be compatible with its intended route of administration.
  • routes of administration include parenteral (e.g., intravenous, intradermal, intraperitoneal or subcutaneous), oral, inhalation, transdermal (topical), intraocular, iontophoretic, and transmucosal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents
  • antibacterial agents such as benzyl alcohol or methyl parabens
  • antioxidants
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • the dosing formulation can be provided in a kit containing all necessary equipment (e.g., vials of drug, vials of diluent, syringes and needles) for a treatment course (e.g., 7 days of treatment).
  • compositions suitable for injectable use can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
  • a composition for parenteral administration must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the aromatic-cationic peptide compositions can include a carrier, which can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • a carrier which can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thiomerasol, and the like.
  • Glutathione and other antioxidants can be included to prevent oxidation.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • typical methods of preparation include vacuum drying and freeze drying, which can yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral compositions generally include an inert diluent or an edible carrier.
  • the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules.
  • Oral compositions can also be prepared using a fluid carrier for use as a mouthwash.
  • Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • the compounds can be delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
  • a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration of a therapeutic compound as described herein can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays.
  • the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. In one embodiment, transdermal administration may be performed my iontophoresis.
  • a therapeutic protein or peptide can be formulated in a carrier system.
  • the carrier can be a colloidal system.
  • the colloidal system can be a liposome, a phospholipid bilayer vehicle.
  • the therapeutic peptide is encapsulated in a liposome while maintaining peptide integrity.
  • there are a variety of methods to prepare liposomes See Lichtenberg et al., Methods Biochem. Anal., 33:337-462 (1988); Anselem et al., Liposome Technology , CRC Press (1993)). Liposomal formulations can delay clearance and increase cellular uptake (See Reddy, Ann. Pharmacother., 34(7-8):915-923 (2000)).
  • An active agent can also be loaded into a particle prepared from pharmaceutically acceptable ingredients including, but not limited to, soluble, insoluble, permeable, impermeable, biodegradable or gastroretentive polymers or liposomes.
  • Such particles include, but are not limited to, nanoparticles, biodegradable nanoparticles, microparticles, biodegradable microparticles, nanospheres, biodegradable nanospheres, microspheres, biodegradable microspheres, capsules, emulsions, liposomes, micelles and viral vector systems.
  • the carrier can also be a polymer, e.g., a biodegradable, biocompatible polymer matrix.
  • the therapeutic peptide can be embedded in the polymer matrix, while maintaining protein integrity.
  • the polymer may be natural, such as polypeptides, proteins or polysaccharides, or synthetic, such as poly ⁇ -hydroxy acids. Examples include carriers made of, e.g., collagen, fibronectin, elastin, cellulose acetate, cellulose nitrate, polysaccharide, fibrin, gelatin, and combinations thereof.
  • the polymer is poly-lactic acid (PLA) or copoly lactic/glycolic acid (PGLA).
  • the polymeric matrices can be prepared and isolated in a variety of forms and sizes, including microspheres and nanospheres. Polymer formulations can lead to prolonged duration of therapeutic effect. (See Reddy, Ann. Pharmacother., 34(7-8):915-923 (2000)). A polymer formulation for human growth hormone (hGH) has been used in clinical trials. (See Kozarich and Rich, Chemical Biology, 2:548-552 (1998)).
  • hGH human growth hormone
  • polymer microsphere sustained release formulations are described in PCT publication WO 99/15154 (Tracy et al.), U.S. Pat. Nos. 5,674,534 and 5,716,644 (both to Zale et al.), PCT publication WO 96/40073 (Zale et al.), and PCT publication WO 00/38651 (Shah et al.).
  • U.S. Pat. Nos. 5,674,534 and 5,716,644 and PCT publication WO 96/40073 describe a polymeric matrix containing particles of erythropoietin that are stabilized against aggregation with a salt.
  • the therapeutic compounds are prepared with carriers that will protect the therapeutic compounds against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
  • Such formulations can be prepared using known techniques.
  • the materials can also be obtained commercially, e.g., from Alza Corporation and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions (including liposomes targeted to specific cells with monoclonal antibodies to cell-specific antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
  • the therapeutic compounds can also be formulated to enhance intracellular delivery.
  • liposomal delivery systems are known in the art, see, e.g., Chonn and Cullis, “Recent Advances in Liposome Drug Delivery Systems,” Current Opinion in Biotechnology 6:698-708 (1995); Weiner, “Liposomes for Protein Delivery: Selecting Manufacture and Development Processes,” Immunomethods, 4(3):201-9 (1994); and Gregoriadis, “Engineering Liposomes for Drug Delivery: Progress and Problems,” Trends Biotechnol., 13(12):527-37 (1995). Mizguchi et al., Cancer Lett., 100:63-69 (1996), describes the use of fusogenic liposomes to deliver a protein to cells both in vivo and in vitro.
  • Dosage, toxicity and therapeutic efficacy of the therapeutic agents can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
  • Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
  • the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose can be estimated initially from cell culture assays.
  • a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
  • IC50 i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms
  • levels in plasma may be measured, for example, by high performance liquid chromatography.
  • an effective amount of the aromatic-cationic peptides ranges from about 0.000001 mg per kilogram body weight per day to about 10,000 mg per kilogram body weight per day.
  • the dosage ranges are from about 0.0001 mg per kilogram body weight per day to about 100 mg per kilogram body weight per day.
  • dosages can be 1 mg/kg body weight or 10 mg/kg body weight every day, every two days or every three days or within the range of 1-10 mg/kg every week, every two weeks or every three weeks.
  • a single dosage of peptide ranges from 0.001-10,000 micrograms per kg body weight.
  • aromatic-cationic peptide concentrations in a carrier range from 0.2 to 2000 micrograms per delivered milliliter.
  • An exemplary treatment regime entails administration once per day or once a week. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, and preferably until the subject shows partial or complete amelioration of symptoms of disease. Thereafter, the patient can be administered a prophylactic regime.
  • a therapeutically effective amount of an aromatic-cationic peptide may be defined as a concentration of peptide at the target tissue of 10 ⁇ 12 to 10 ⁇ 6 molar, e.g., approximately 10 ⁇ 7 molar. This concentration may be delivered by systemic doses of 0.001 to 100 mg/kg or equivalent dose by body surface area. The schedule of doses would be optimized to maintain the therapeutic concentration at the target tissue, most preferably by single daily or weekly administration, but also including continuous administration (e.g., parenteral infusion or transdermal application).
  • treatment of a subject with a therapeutically effective amount of the therapeutic compositions described herein can include a single treatment or a series of treatments.
  • the mammal treated in accordance present methods can be any mammal, including, for example, farm animals, such as sheep, pigs, cows, and horses; pet animals, such as dogs and cats; laboratory animals, such as rats, mice and rabbits.
  • the mammal is a human.
  • the aromatic-cationic peptides may be combined with one or more additional agents for the prevention or treatment of heart failure.
  • Drug treatment for heart failure typically involves diuretics, ACE inhibitors, digoxin (also called digitalis), calcium channel blockers, and beta-blockers.
  • thiazide diuretics such as hydrochlorothiazide at 25-50 mg/day or chlorothiazide at 250-500 mg/day, are useful.
  • supplemental potassium chloride may be needed, since chronic diuresis causes hypokalemis alkalosis.
  • thiazide diuretics usually are not effective in patients with advanced symptoms of heart failure.
  • Typical doses of ACE inhibitors include captopril at 25-50 mg/day and quinapril at 10 mg/day.
  • the aromatic-cationic peptide is combined with an adrenergic beta-2 agonist.
  • adrenergic beta-2 agonist refers to adrenergic beta-2 agonists and analogues and derivatives thereof, including, for example, natural or synthetic functional variants which have adrenergic beta-2 agonist biological activity, as well as fragments of an adrenergic beta-2 agonist having adrenergic beta-2 agonist biological activity.
  • adrenergic beta-2 agonist biological activity refers to activity that mimics the effects of adrenaline and noradrenaline in a subject and which improves myocardial contractility in a patient having heart failure.
  • adrenergic beta-2 agonists include, but are not limited to, clenbuterol, albuterol, formeoterol, levalbuterol, metaproterenol, pirbuterol, salmeterol, and terbutaline.
  • the aromatic-cationic peptide is combined with an adrenergic beta-1 antagonist.
  • Adrenergic beta-1 antagonists and adrenergic beta-1 blockers refer to adrenergic beta-1 antagonists and analogues and derivatives thereof, including, for example, natural or synthetic functional variants which have adrenergic beta-1 antagonist biological activity, as well as fragments of an adrenergic beta-1 antagonist having adrenergic beta-1 antagonist biological activity.
  • Adrenergic beta-1 antagonist biological activity refers to activity that blocks the effects of adrenaline on beta receptors.
  • adrenergic beta-1 antagonists include, but are not limited to, acebutolol, atenolol, betaxolol, bisoprolol, esmolol, and metoprolol.
  • Clenbuterol for example, is available under numerous brand names including Spiropent® (Boehinger Ingelheim), Broncodil® (Von Boch I), Broncoterol® (Quimedical PT), Cesbron® (Fidelis PT), and Clenbuter® (Biomedica Foscama).
  • Spiropent® Boehinger Ingelheim
  • Broncodil® Von Boch I
  • Broncoterol® Quimedical PT
  • Cesbron® Fidelis PT
  • Clenbuter® Biomedica Foscama
  • Metoprolol in particular, is commercially available under the brand names Lopressor® (metoprolol tartate) manufactured by Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, N.J. 07936-1080.
  • Lopressor® Generic versions of Lopressor® are also available from Mylan Laboratories Inc., 1500 Corporate Drive, Suite 400, Canonsburg, Pa. 15317; and Watson Pharmaceuticals, Inc., 360 Mt. Kemble Ave. Morristown, N.J. 07962. Metoprolol is also commercially available under the brand name Toprol XL®, manufactured by Astra Zeneca, LP.
  • an additional therapeutic agent is administered to a subject in combination with an aromatic cationic peptide, such that a synergistic therapeutic effect is produced.
  • a “synergistic therapeutic effect” refers to a greater-than-additive therapeutic effect which is produced by a combination of two therapeutic agents, and which exceeds that which would otherwise result from individual administration of either therapeutic agent alone. Therefore, lower doses of one or both of the therapeutic agents may be used in treating heart failure, resulting in increased therapeutic efficacy and decreased side-effects.
  • the multiple therapeutic agents may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may vary from more than zero weeks to less than four weeks. In addition, the combination methods, compositions and formulations are not to be limited to the use of only two agents.
  • the mitochondrial targeted antioxidant peptide SS-31 was used to determine the role of NADPH oxidase and mitochondria in Angiotensin II (Ang II)-induced cardiomyopathy, as well as in G ⁇ q overexpressing mice with heart failure.
  • Neonatal mouse cardiomyocyte culture and flow cytometry Ventricles from mouse neonates younger than 72 hours were dissected, minced, and enzymatically digested with Blendzyme 4 (45 ⁇ g/ml, Roche). After enzymatic digestion, cardiomyocytes were enriched using differential pre-plating for 2 hours, then seeded on fibronectin-coated culture dishes for 24 hours in DMEM (Gibco), with 20% Fetal Bovine Serum (Sigma) and 25 ⁇ M Arabinosylcytosine (Sigma).
  • Cardiomyocytes were stimulated with Angiotensin II (1 ⁇ M) for 3 hours in serum-free DMEM containing 0.5% insulin transferrin-selenium (Sigma), 2 mM glutamine, and 1 mg/ml of BSA. Cardiomyocytes were simultaneously treated with either of the following: SS-31 (1 nM), N-acetyl cysteine (NAC: 0.5 mM), or PBS control. To measure mitochondrial superoxide concentration, Mitosox (5 ⁇ M) was incubated for 30 min at 37° C. to load cardiomyocytes, followed by 2 washes, with Hanks Balanced Salt Solution. Samples were analyzed using excitation/emission of 488/625 nm by flow cytometry. Flow data was analyzed using FCS Express (De Novo Software, Los Angeles, Calif.), and presented as histogram distributions of Mitosox fluorescence intensity.
  • FCS Express De Novo Software, Los Angeles, Calif.
  • mice were housed in a barrier specific pathogen-free facility. Six to ten mice were included in each experimental group (Saline, Ang II, Ang II+SS-31, WT, G ⁇ q, G ⁇ q+SS-31). A pressor dose of Ang II (1.1 mg/kg/d) was continuously administered for 4 weeks using subcutaneous Alzet 1004 osmotic minipumps, with or without addition of SS-31 (3 mg/kg/d). Echocardiography was performed at baseline and after 4 weeks of pump implantation using a Siemens Acuson CV-70 equipped with a 13 MHz probe.
  • MPI was calculated as the ratio of the sum of isovolemic contraction and relaxation time to LV ejection time. An increase in MPI is an indication that a greater fraction of systole is spent to cope with the pressure changes during the isovolemic phases.
  • SS-31 peptide effect in Ang II treated mice a genetic mouse model of Rosa-26 inducible-mCAT was included, in which mitochondrial catalase was overexpressed two weeks before Ang II treatment.
  • Blood pressure was measured in a separate group of mice by telemetry using an intravascular catheter PA-C 10 (DSI, MN), in which measurement was performed every three hours starting from 2 days before pump placement until 2 days after Ang pump placement. After this time, a new pump loaded with Ang II+SS-31 was inserted, followed by another 2 days of recording to see if SS-31 had an effect on blood pressure.
  • DSI intravascular catheter PA-C 10
  • Quantitative Pathology Ventricular tissues were cut into transverse slices, and subsequently embedded with paraffin, sectioned, and subjected to Masson Trichrome staining. Quantitative analysis of fibrosis was performed by measuring the percentage of blue-staining fibrotic tissue relative to the total cross-sectional area of the ventricles.
  • mitochondrial protein carbonyl groups For mitochondrial protein extraction, ventricular tissues were homogenized in mitochondrial isolation buffer (1 mM EGTA, 10 mM HEPES, 250 mM sucrose, 10 mM Tris-HCl, pH 7.4). The lysates were centrifuged for 7 min at 800 g in 4° C. The supernatants were then centrifuged for 30 min at 4000 g in 4° C. The crude mitochondria pellets were resuspended in small volume of mitochondrial isolation buffer, sonicated on ice to disrupt the membrane, and treated with 1% streptomycin sulfate to precipitate mitochondrial nucleic acids.
  • the OxiSelectTM Protein Carbonyl ELISA Kit (Cell Biolabs) was used to analyze 1 ⁇ g of protein sample per assay.
  • the ELISA was performed according to the instruction manual, with slight modification. Briefly, protein samples were reacted with dinitrophenylhydrazine (DNPH) and probed with anti-DNPH antibody, followed by HRP conjugated secondary antibody. The anti-DNPH antibody and HRP conjugated secondary antibody concentrations were 1:2500 and 1:4000, respectively.
  • Quantitative PCR Gene expression was quantified by quantitative real time PCR using an Applied Biosystems 7900 themocycler with Taqman Gene Expression Assays on Demand, which included: PGC1- ⁇ (Mm00731216), TFAM (Mm00447485), NRF-1 (Mm00447996), NRF-2 (Mm00487471), Collagen 1a2 (Mm00483937), and ANP (Mm01255747). Expression assays were normalized to 18S RNA.
  • NADPH Oxidase activity The NADPH oxidase assay was performed as described elsewhere. In brief, 10 ⁇ g of ventricular protein extract was incubated with dihydroethidium (DHE, 10 ⁇ M), sperm DNA (1.25 ⁇ g/ml), and NADPH (50 ⁇ M) in PBS/DTPA (containing 100 ⁇ M DTPA), The assay was incubated at 37° C. in the dark for 30 min and the fluorescence was detected using excitation/emission of 490/580 nm.
  • DHE dihydroethidium
  • sperm DNA 1.25 ⁇ g/ml
  • NADPH 50 ⁇ M
  • PBS/DTPA containing 100 ⁇ M DTPA
  • Total protein (25 ⁇ g) was separated on NuPAGE 4-12% Bis-Tris gel (Invitrogen) and transferred to 0.45 ⁇ m PVDF membrane (Millipore), and then blocked in 5% non-fat dry milk in Tris-buffer solution with 0.1% Tween-20 for 1 hour. Primary antibodies were incubated overnight, and secondary antibodies were incubated for 1 hour. The primary antibodies included: rabbit monoclonal anti-cleaved caspase-3 (Cell Signaling), mouse monoclonal anti-GAPDH (Millipore), rabbit polyclonal phospho-p38 MAP kinase (Cell Signaling), and mouse monoclonal anti-p38 (Santa Cruz Biotechnology). The enhanced chemiluminescence method (Thermo Scientific) was used for detection. Image Quant ver.2.0 was used to quantified the relative band density as a ratio to GAPDH (internal control). All samples were normalized to the same cardiac protein sample.
  • Ang-II increased mitochondrial ROS in neonatal cardiomyoctyes, which was alleviated by mitochondrial antioxidant peptide SS-31.
  • Flow cytometry analysis demonstrated that Angiotensin II increased Mitosox fluorescence (an indicator of mitochondrial superoxide) by approximately 2-fold in neonatal cardiomyocytes.
  • NAC N-acetyl cysteine
  • SS-31 reduced Ang II-induced mitosox fluorescence to the level similar to that of saline treated cardiomyocytes ( FIG. 1 ).
  • SS-31 peptide ameliorates Ang-II induced cardiomyopathy despite the absence of blood pressure lowering effect.
  • a pressor dose of Ang II 1.1 mg/kg/d
  • Alzet 1004 osmotic minipumps As shown in FIGS. 2A and 2B , intravascular telemetry revealed that this dose of Ang II significantly increased systolic and diastolic blood pressure by 25-28 mm Hg above baseline (BP: 118.8 ⁇ 4.0/94.5 ⁇ 3.5 mm Hg at baseline vs. 146.0 ⁇ 5.6/119.3 ⁇ 4.0 mm Hg after Ang II, p ⁇ 0.001). Simultaneous administration of SS-31 (3 mg/kg/d) did not show any effect on blood pressure ( FIG. 2 ).
  • LVMI left ventricular mass index
  • i-mCAT catalase targeted to mitochondria
  • FIG. 4A demonstrated that Ang II increased heart weights by 45% above those of saline treated control hearts (5.3 ⁇ 0.18 in saline vs.
  • FIG. 4C The cardiac pathology was examined by Masson trichrome staining, which demonstrated perivascular fibrosis and interstitial fibrosis after 4 weeks of Ang II ( FIG. 4C ). Quantitative image analysis of ventricular fibrosis (blue staining on trichrome) showed that Ang II significantly increase ventricular fibrosis by greater than 3 fold, which was fully attenuated by SS-31 ( FIG. 4D ). The increase in cardiac fibrosis was confirmed by quantitative PCR of the procollagen 1a2 gene, the main component of fibrosis. As shown in FIG. 4E , Ang II increased Coll 1a2 gene expression by ⁇ 2.5 fold, which was almost fully attenuated by SS-31 administration.
  • Peroxisome proliferator-activated receptor gamma co-activator has been shown to be a master regulator of mitochondrial biogenesis, regulating nuclear respiratory factors (NRFs) and mitochondrial transcription factor A (TFAM), which transcribe nuclear DNA and mitochondrial DNA encoded mitochondrial proteins, respectively.
  • NEFs nuclear respiratory factors
  • TFAM mitochondrial transcription factor A
  • Ang II also induced the expression of PGC-1 ⁇ and its downstream target genes, including TFAM, NRF-1 and NRF-2 ( FIG. 5B ).
  • the mitochondrial antioxidant SS-31 was found to fully prevent the upregulation of PGC-1 ⁇ and all the downstream target genes after 4 weeks of Ang II (p ⁇ 0.05 for all, FIG. 5B ).
  • MAPK mitogen activated protein kinase
  • G ⁇ q protein is coupled to receptors for catecholamines and Ang II, all of which are known to be key mediators in hypertensive cardiovascular diseases.
  • Ang II a genetic mouse model with cardiac specific overexpression of G ⁇ q was used, which causes heart failure in mice by 14-16 weeks of age.
  • the G ⁇ q mice in this study had impairment of systolic function at 16 weeks age, as shown by a substantial decline in FS ( FIG. 7A ), with enlargement of the LV chamber ( FIG. 7B ), impairment of diastolic function indicated by decreased Ea/Aa ( FIG.
  • G ⁇ q is a subunit of the G-protein that is coupled to adrenergic and angiotensin II receptors. Cardiac-specific overexpression of G ⁇ q has been shown to cause heart failure in mice by 14-16 weeks of age, despite the absence of increased blood pressure. Twelve-week-old G ⁇ q mice were treated with SS-31 for 4 weeks and demonstrated that SS-31 partially rescued the heart failure phenotype in the G ⁇ q mouse model. SS-31 significantly ameliorated systolic dysfunction, cardiac hypertrophy, and improved overall myocardial performance ( FIG. 7A , D, E). A trend showing that SS-31 attenuated chamber enlargement, diastolic dysfunction and lung congestion was also observed ( FIG. 7B , C and E).
  • Hypertension is a highly prevalent disease that imposes a major risk for the development of atherosclerosis, cardiomyopathy, stroke, sudden cardiac death and heart failure.
  • Hypertension-induced heart failure may be manifested as systolic heart failure or heart failure with preserved ejection fraction (HFpEF); the latter accounts for nearly half of the patients with heart failure, especially among female elderly patients, and the prognosis of HFpEF is marginally better than that of systolic heart failure.
  • HFpEF preserved ejection fraction
  • Several clinical trials have shown that the current recommended antihypertensive medications are effective in reducing major cardiovascular events and the development of heart failure by only up to 50%. Although this treatment reduces mortality and improves quality of life in patients with established systolic heart failure, there is no convincing evidence for any effective treatment of HFpEF. This underscores the urgent need to develop new prevention and treatment strategies for hypertensive cardiovascular diseases.
  • the mitochondrial targeted antioxidant SS-31 is beneficial in amelioration of cardiomyopathy resulting from prolonged Ang II stimulation as well as G ⁇ q overexpression, suggesting its potential clinical application for target organ protection in hypertensive cardiovascular diseases.
  • the aromatic-cationic peptides of the invention are useful in methods for treating or preventing HF in mammalian subjects.
  • Ang II is infused by osmotic minipump (4 weeks @ 1.1 mg/kg/d) to the mice in the following groups: (1) wild type (WT); (2) transgenic mice exhibiting cardiac specific overexpression of angiotensinogen (Tg); (3) mice overexpressing catalase targeted to peroxisomes (pCAT); mice overexpressing catalase targeting to mitochondria (mCAT); and (4) mice expressing an inducible mCAT (i-mCAT).
  • WT wild type
  • Tg transgenic mice exhibiting cardiac specific overexpression of angiotensinogen
  • pCAT mice overexpressing catalase targeted to peroxisomes
  • mCAT mice overexpressing catalase targeting to mitochondria
  • i-mCAT mice expressing an inducible mCAT
  • the study is carried out in C57B16 mice in the following treatment groups: (1) WT (wild-type C57B16 mice); (2) pCAT (overexpression of catalase targeted to peroxisomes); (3) mCAT (overexpression of catalase targeted to mitochondria);(4) G ⁇ q (overexpression of G ⁇ aq); (5) G ⁇ q/mCAT (overexpression of G ⁇ q and mitochondria-targeted catalase); (6) G ⁇ q/pCAT (overexpression of G ⁇ q and peroxisome-targeted catalase); and (7) G ⁇ q+SS-peptides (G ⁇ q mice treated with SS-20).
  • WT wild-type C57B16 mice
  • pCAT overexpression of catalase targeted to peroxisomes
  • mCAT overexpression of catalase targeted to mitochondria
  • G ⁇ q overexpression of G ⁇ aq
  • G ⁇ q/mCAT overexpression of G ⁇ q and mitochondria-targeted catalase
  • G ⁇ q/pCAT overexpression of G ⁇ q and peroxisome-targeted catalase
  • Cardiac function is determined by echocardiography (Acuson CV-70, Siemens Medical Systems, Malvern, Pa.) using standard imaging planes—M-mode, conventional, and tissue Doppler imaging.
  • M-mode myocardial performance index
  • LVMI left ventricular mass index
  • Ea/Aa ratio Ea/Aa ratio
  • Treatment with SS-20 is predicted to reduce Ang II-induced HF or G ⁇ q-induced HF as evidenced by a reduction in LVMI and MPT, and no increase in heart weight. There is also predicted to be an improvement in both systolic and diastolic function.
  • the protection provided by SS-20 is expected to be similar to the protection provided by overexpression of catalase in mitochondria. As such, aromatic-cationic peptide SS-20 is useful in methods at preventing or treating hypertensive cardiomyopathy and HF in mammalian subjects.
  • a range includes each individual member.
  • a group having 1-3 cells refers to groups having 1, 2, or 3 cells.
  • a group having 1-5 cells refers to groups having 1, 2, 3, 4, or 5 cells, and so forth.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
US12/897,325 2009-10-05 2010-10-04 Methods for the prevention or treatment of heart failure Abandoned US20110082084A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US12/897,325 US20110082084A1 (en) 2009-10-05 2010-10-04 Methods for the prevention or treatment of heart failure
US14/035,577 US20140100166A1 (en) 2009-10-05 2013-09-24 Methods for the prevention or treatment of heart failure
US14/727,513 US20160106800A1 (en) 2009-10-05 2015-06-01 Methods for the prevention or treatment of heart failure
US15/723,259 US20180236025A1 (en) 2009-10-05 2017-10-03 Methods for the prevention or treatment of heart failure
US16/796,940 US11534476B2 (en) 2009-10-05 2020-02-20 Methods for the prevention or treatment of heart failure
US17/084,046 US20210187056A1 (en) 2009-10-05 2020-10-29 Methods for the prevention or treatment of heart failure
US18/079,604 US12102659B2 (en) 2009-10-05 2022-12-12 Methods for the prevention or treatment of heart failure

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24868109P 2009-10-05 2009-10-05
US28948309P 2009-12-23 2009-12-23
US12/897,325 US20110082084A1 (en) 2009-10-05 2010-10-04 Methods for the prevention or treatment of heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/035,577 Continuation US20140100166A1 (en) 2009-10-05 2013-09-24 Methods for the prevention or treatment of heart failure

Publications (1)

Publication Number Publication Date
US20110082084A1 true US20110082084A1 (en) 2011-04-07

Family

ID=43823652

Family Applications (7)

Application Number Title Priority Date Filing Date
US12/897,325 Abandoned US20110082084A1 (en) 2009-10-05 2010-10-04 Methods for the prevention or treatment of heart failure
US14/035,577 Abandoned US20140100166A1 (en) 2009-10-05 2013-09-24 Methods for the prevention or treatment of heart failure
US14/727,513 Abandoned US20160106800A1 (en) 2009-10-05 2015-06-01 Methods for the prevention or treatment of heart failure
US15/723,259 Abandoned US20180236025A1 (en) 2009-10-05 2017-10-03 Methods for the prevention or treatment of heart failure
US16/796,940 Active 2030-12-18 US11534476B2 (en) 2009-10-05 2020-02-20 Methods for the prevention or treatment of heart failure
US17/084,046 Abandoned US20210187056A1 (en) 2009-10-05 2020-10-29 Methods for the prevention or treatment of heart failure
US18/079,604 Active US12102659B2 (en) 2009-10-05 2022-12-12 Methods for the prevention or treatment of heart failure

Family Applications After (6)

Application Number Title Priority Date Filing Date
US14/035,577 Abandoned US20140100166A1 (en) 2009-10-05 2013-09-24 Methods for the prevention or treatment of heart failure
US14/727,513 Abandoned US20160106800A1 (en) 2009-10-05 2015-06-01 Methods for the prevention or treatment of heart failure
US15/723,259 Abandoned US20180236025A1 (en) 2009-10-05 2017-10-03 Methods for the prevention or treatment of heart failure
US16/796,940 Active 2030-12-18 US11534476B2 (en) 2009-10-05 2020-02-20 Methods for the prevention or treatment of heart failure
US17/084,046 Abandoned US20210187056A1 (en) 2009-10-05 2020-10-29 Methods for the prevention or treatment of heart failure
US18/079,604 Active US12102659B2 (en) 2009-10-05 2022-12-12 Methods for the prevention or treatment of heart failure

Country Status (7)

Country Link
US (7) US20110082084A1 (fr)
EP (5) EP2764871A1 (fr)
JP (6) JP2013506696A (fr)
CN (2) CN103845724A (fr)
CA (1) CA2776581C (fr)
HK (1) HK1217293A1 (fr)
WO (1) WO2011044044A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039766A1 (en) * 2009-08-12 2011-02-17 Szeto Hazel H Methods for preventing or treating metabolic syndrome
US20130190244A1 (en) * 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2014066419A3 (fr) * 2012-10-22 2014-06-12 Stealth Peptides International, Inc. Méthodes pour la réduction de risques associés à une insuffisance cardiaque et de facteurs associés à celle-ci
WO2014185952A1 (fr) * 2013-05-14 2014-11-20 Stealth Peptides International, Inc. Méthodes de prévention ou de traitement du remodelage ventricualire gauche
WO2014193951A1 (fr) * 2013-05-28 2014-12-04 Dana-Farber Cancer Institute, Inc. Thérapie par inhibition de bet pour une cardiopathie
US20160194708A1 (en) * 2013-06-26 2016-07-07 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US20160228487A1 (en) * 2013-03-01 2016-08-11 Stealth Biotherapeutics Corp. Methods and compositions for the prevention or treatment of barth syndrome
US20170027474A1 (en) * 2015-07-30 2017-02-02 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
WO2018195537A1 (fr) * 2017-04-21 2018-10-25 Northeast Ohio Medical University Méthodes de traitement de l'insuffisance cardiaque
US20190022165A1 (en) * 2016-03-02 2019-01-24 Stealth Biotherapeutics Corp Methods and compositions for the treatment and prevention of pulmonary arterial hypertension
WO2020118035A1 (fr) * 2018-12-06 2020-06-11 Stealth Biotherapeutics Corp Procédés et compositions destinés au traitement du syndrome de sengers
EP3673913A1 (fr) * 2013-03-01 2020-07-01 Stealth Biotherapeutics Corp Procédés pour le traitement d'une maladie mitochondriale
US20210220431A1 (en) * 2013-08-02 2021-07-22 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
US11534476B2 (en) 2009-10-05 2022-12-27 Cornell University Methods for the prevention or treatment of heart failure
US11575689B2 (en) 2008-03-18 2023-02-07 Mcafee, Llc System, method, and computer program product for dynamically configuring a virtual environment for identifying unwanted data
US20230109564A1 (en) * 2016-01-06 2023-04-06 Stealth Biotherapeutics Inc. Methods and compositions for the prevention and treatment of duchenne muscular dystrophy
EP4168425A4 (fr) * 2020-06-17 2024-06-19 Stealth BioTherapeutics Inc. Méthodes et compositions pour le traitement de la dystrophie musculaire

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636378B2 (en) * 2012-03-30 2017-05-02 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment neuropathy
WO2016004441A1 (fr) * 2014-07-03 2016-01-07 Stealth Peptides International, Inc. Méthodes de prévention ou de traitement d'une lésion d'infarctus aigu du myocarde
CA3020393A1 (fr) 2016-04-11 2017-10-19 Carnot, Llc Peptides chiraux
WO2018005990A2 (fr) * 2016-07-01 2018-01-04 Marshall University Research Corporation Compositions et méthodes pour traiter la cardiomyopathie urémique
CN112111003B (zh) * 2019-06-20 2022-02-11 中国农业大学 含有me序列的一类新型抑制血小板聚集和抗血栓形成寡肽
EP3771467A1 (fr) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 pour la prévention et/ou le traitement de l'anévrisme
CN116390723A (zh) 2020-09-09 2023-07-04 社会利益网络公司 用于将生物素递送至线粒体的方法和组合物

Citations (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4732898A (en) * 1986-04-29 1988-03-22 Warner-Lambert Company 2-(2-aryl-2-oxoalkylidene) analogs of-3,5-pyridinedicarboxylic acid dialkyl esters useful for treatment of cardiovascular disorders
US5312899A (en) * 1988-06-30 1994-05-17 Biochem Pharma, Inc. Dermorphin analogs
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5993848A (en) * 1995-06-09 1999-11-30 Takeda Chemical Industries, Ltd. Dissolution liquid for drug in iontophoresis
US5994372A (en) * 1995-09-12 1999-11-30 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) * 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6468798B1 (en) * 1991-12-17 2002-10-22 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol and liposome-based delivery
US6503713B1 (en) * 1999-10-04 2003-01-07 University Of Medicine And Dentistry Of New Jersey Methods for identifying RNA binding compounds
US20030060415A1 (en) * 1995-11-01 2003-03-27 Chiron Corporation Treatment of a coronary condition by delivery of therapeutics to the pericardial space
US6703483B1 (en) * 1999-03-16 2004-03-09 Cornell Research Foundation, Inc. Compounds useful in pain management
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20040266675A1 (en) * 2001-10-01 2004-12-30 Mark Anderson Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
US6859662B2 (en) * 2000-12-21 2005-02-22 Tonino Bombardini Method and device for the diagnosis and therapy of chronic heart failure
US20050096333A1 (en) * 2003-09-30 2005-05-05 Sundeep Dugar Quinazoline derivatives as medicaments
US6900179B2 (en) * 1997-07-31 2005-05-31 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US20070093969A1 (en) * 2002-11-22 2007-04-26 Mendrick Donna L Molecular nephrotoxicology modeling
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080014604A1 (en) * 2004-06-07 2008-01-17 Prasad Devarajan Method for the early detection of renal injury
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US7541340B2 (en) * 2005-09-16 2009-06-02 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
US7550439B2 (en) * 2004-01-23 2009-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US7576061B2 (en) * 2003-02-04 2009-08-18 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
US20090221514A1 (en) * 2008-02-26 2009-09-03 Szeto Hazel H Methods for prevention and treatment of acute renal injury
US20090253641A1 (en) * 2008-02-07 2009-10-08 Neufer P Darrell Methods for preventing or treating insulin resistance
US7704954B2 (en) * 2003-05-01 2010-04-27 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US7776925B2 (en) * 2002-03-06 2010-08-17 Duke University Reversing, postponing or preventing the occurrence of GTN tolerance and/or generation of reactive oxygen species from mitochondria
EP3906933A1 (fr) 2009-03-20 2021-11-10 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-diméthyltyrosine-lys-phe-nh2 pour la prévention des complications secondaires des brûlures
EP2464371B1 (fr) * 2009-08-12 2016-03-16 Cornell University Procédés de prévention ou de traitement du syndrome métabolique
EP2764871A1 (fr) 2009-10-05 2014-08-13 Cornell University Procédés pour la prévention ou le traitement de l'insuffisance cardiaque

Patent Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4732898A (en) * 1986-04-29 1988-03-22 Warner-Lambert Company 2-(2-aryl-2-oxoalkylidene) analogs of-3,5-pyridinedicarboxylic acid dialkyl esters useful for treatment of cardiovascular disorders
US5312899A (en) * 1988-06-30 1994-05-17 Biochem Pharma, Inc. Dermorphin analogs
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US6468798B1 (en) * 1991-12-17 2002-10-22 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol and liposome-based delivery
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5993848A (en) * 1995-06-09 1999-11-30 Takeda Chemical Industries, Ltd. Dissolution liquid for drug in iontophoresis
US5994372A (en) * 1995-09-12 1999-11-30 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US20030060415A1 (en) * 1995-11-01 2003-03-27 Chiron Corporation Treatment of a coronary condition by delivery of therapeutics to the pericardial space
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US6900179B2 (en) * 1997-07-31 2005-05-31 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) * 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6703483B1 (en) * 1999-03-16 2004-03-09 Cornell Research Foundation, Inc. Compounds useful in pain management
US6503713B1 (en) * 1999-10-04 2003-01-07 University Of Medicine And Dentistry Of New Jersey Methods for identifying RNA binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US7732398B2 (en) * 2000-07-18 2010-06-08 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6859662B2 (en) * 2000-12-21 2005-02-22 Tonino Bombardini Method and device for the diagnosis and therapy of chronic heart failure
US20040266675A1 (en) * 2001-10-01 2004-12-30 Mark Anderson Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
US20070093969A1 (en) * 2002-11-22 2007-04-26 Mendrick Donna L Molecular nephrotoxicology modeling
US7576061B2 (en) * 2003-02-04 2009-08-18 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
US7718620B2 (en) * 2003-02-04 2010-05-18 Cornell Research Foundation, Inc. Methods for preventing or treating ischemia-reperfusion injury of the kidney
US7704954B2 (en) * 2003-05-01 2010-04-27 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US20050096333A1 (en) * 2003-09-30 2005-05-05 Sundeep Dugar Quinazoline derivatives as medicaments
US7550439B2 (en) * 2004-01-23 2009-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US7781405B2 (en) * 2004-01-23 2010-08-24 Cornell Research Foundation Methods for reducing oxidative damage
US20080014604A1 (en) * 2004-06-07 2008-01-17 Prasad Devarajan Method for the early detection of renal injury
US7541340B2 (en) * 2005-09-16 2009-06-02 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
US7811987B2 (en) * 2005-09-16 2010-10-12 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
US20090253641A1 (en) * 2008-02-07 2009-10-08 Neufer P Darrell Methods for preventing or treating insulin resistance
US20090221514A1 (en) * 2008-02-26 2009-09-03 Szeto Hazel H Methods for prevention and treatment of acute renal injury

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11575689B2 (en) 2008-03-18 2023-02-07 Mcafee, Llc System, method, and computer program product for dynamically configuring a virtual environment for identifying unwanted data
US20110039766A1 (en) * 2009-08-12 2011-02-17 Szeto Hazel H Methods for preventing or treating metabolic syndrome
US12102659B2 (en) 2009-10-05 2024-10-01 Cornell University Methods for the prevention or treatment of heart failure
US11534476B2 (en) 2009-10-05 2022-12-27 Cornell University Methods for the prevention or treatment of heart failure
US20130190244A1 (en) * 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2014066419A3 (fr) * 2012-10-22 2014-06-12 Stealth Peptides International, Inc. Méthodes pour la réduction de risques associés à une insuffisance cardiaque et de facteurs associés à celle-ci
EP4397314A1 (fr) * 2012-10-22 2024-07-10 Stealth BioTherapeutics Inc. Traitement du remodelage ventriculaire gauche
US20230190859A1 (en) * 2012-10-22 2023-06-22 Stealth Biotherapeutics Inc. Methods for reducing risks associated with heart failure and factors associated therewith
EP4005582A1 (fr) * 2012-10-22 2022-06-01 Stealth BioTherapeutics Inc. Traitement du remodelage ventriculaire gauche
EP3586862A1 (fr) * 2012-10-22 2020-01-01 Stealth Peptides International, Inc. Procédés de réduction des risques associés à l'insuffisance cardiaque et facteurs associés
US20180147251A1 (en) * 2013-03-01 2018-05-31 Stealth Biotherapeutics Corp. Methods and compositions for the prevention or treatment of barth syndrome
EP3626252A1 (fr) * 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Procédés et compositions de prévention ou de traitement du syndrome de barth
US11771734B2 (en) 2013-03-01 2023-10-03 Stealth Biotherapeutics Inc. Methods and compositions for the prevention or treatment of Barth syndrome
US20160228487A1 (en) * 2013-03-01 2016-08-11 Stealth Biotherapeutics Corp. Methods and compositions for the prevention or treatment of barth syndrome
US11083771B2 (en) 2013-03-01 2021-08-10 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of Barth Syndrome
US11083772B2 (en) * 2013-03-01 2021-08-10 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of Barth Syndrome
US10793597B2 (en) 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
US9687519B2 (en) * 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
EP3673913A1 (fr) * 2013-03-01 2020-07-01 Stealth Biotherapeutics Corp Procédés pour le traitement d'une maladie mitochondriale
EP3586864A1 (fr) * 2013-05-14 2020-01-01 Stealth Biotherapeutics Corp Procédés de prévention ou de traitement du remodelage ventriculaire gauche
CN110051843A (zh) * 2013-05-14 2019-07-26 康德生物医疗技术公司 预防或治疗左心室重塑的方法
WO2014185952A1 (fr) * 2013-05-14 2014-11-20 Stealth Peptides International, Inc. Méthodes de prévention ou de traitement du remodelage ventricualire gauche
US20190358286A1 (en) * 2013-05-14 2019-11-28 Stealth Biotherapeutics Corp. Methods for the prevention or treatment of left ventricle remodeling
CN105579054A (zh) * 2013-05-14 2016-05-11 康德生物医疗技术公司 预防或治疗左心室重塑的方法
WO2014193951A1 (fr) * 2013-05-28 2014-12-04 Dana-Farber Cancer Institute, Inc. Thérapie par inhibition de bet pour une cardiopathie
US20160194708A1 (en) * 2013-06-26 2016-07-07 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US11312993B2 (en) 2013-06-26 2022-04-26 Stealth Biotherapeutics Inc. Methods and compositions for detecting and diagnosing diseases and conditions
US20210220431A1 (en) * 2013-08-02 2021-07-22 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
US11672841B2 (en) * 2013-08-02 2023-06-13 Stealth Biotherapeutics Inc. Methods for treating heart disease in a subject with Friedreich's ataxia by an aromatic-cationic peptide
US11744478B2 (en) 2015-07-30 2023-09-05 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
US20170027474A1 (en) * 2015-07-30 2017-02-02 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
US10368774B2 (en) * 2015-07-30 2019-08-06 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
US20230109564A1 (en) * 2016-01-06 2023-04-06 Stealth Biotherapeutics Inc. Methods and compositions for the prevention and treatment of duchenne muscular dystrophy
US20190022165A1 (en) * 2016-03-02 2019-01-24 Stealth Biotherapeutics Corp Methods and compositions for the treatment and prevention of pulmonary arterial hypertension
WO2018195537A1 (fr) * 2017-04-21 2018-10-25 Northeast Ohio Medical University Méthodes de traitement de l'insuffisance cardiaque
US11911384B2 (en) 2017-04-21 2024-02-27 Northeast Ohio Medical University Vasodilators for treatment of heart failure
US11324748B2 (en) 2017-04-21 2022-05-10 Northeast Ohio Medical University Vasodilators for treatment of heart failure
US11931397B2 (en) 2018-12-06 2024-03-19 Stealth Biotherapeutics Inc. Methods and compositions for the treatment of Sengers syndrome
WO2020118035A1 (fr) * 2018-12-06 2020-06-11 Stealth Biotherapeutics Corp Procédés et compositions destinés au traitement du syndrome de sengers
EP4168425A4 (fr) * 2020-06-17 2024-06-19 Stealth BioTherapeutics Inc. Méthodes et compositions pour le traitement de la dystrophie musculaire

Also Published As

Publication number Publication date
US20230285499A1 (en) 2023-09-14
EP2485749A4 (fr) 2013-07-24
US20180236025A1 (en) 2018-08-23
CN102711785A (zh) 2012-10-03
JP2013506696A (ja) 2013-02-28
US20140100166A1 (en) 2014-04-10
JP2015163609A (ja) 2015-09-10
JP2016190876A (ja) 2016-11-10
US20200188470A1 (en) 2020-06-18
JP2022046811A (ja) 2022-03-23
US20210187056A1 (en) 2021-06-24
HK1217293A1 (zh) 2017-01-06
EP2485749A1 (fr) 2012-08-15
EP3120860A1 (fr) 2017-01-25
JP7382607B2 (ja) 2023-11-17
CA2776581C (fr) 2020-12-15
CA2776581A1 (fr) 2011-04-14
WO2011044044A1 (fr) 2011-04-14
US12102659B2 (en) 2024-10-01
JP7017762B2 (ja) 2022-02-09
JP6429835B2 (ja) 2018-11-28
EP2764871A1 (fr) 2014-08-13
EP3120860B1 (fr) 2019-06-26
EP2944317A1 (fr) 2015-11-18
EP3603658A1 (fr) 2020-02-05
JP2018203764A (ja) 2018-12-27
JP2020097627A (ja) 2020-06-25
US20160106800A1 (en) 2016-04-21
US11534476B2 (en) 2022-12-27
CN103845724A (zh) 2014-06-11

Similar Documents

Publication Publication Date Title
US12102659B2 (en) Methods for the prevention or treatment of heart failure
US11266709B2 (en) Methods for the regulation of matrix metalloproteinase expression
US20220296671A1 (en) Methods for the prevention or treatment of left ventricle remodeling
US20200113966A1 (en) Methods and compositions for regulating srca2a expression levels in myocardial infarction

Legal Events

Date Code Title Description
AS Assignment

Owner name: CORNELL UNIVERSITY, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SZETO, HAZEL H.;REEL/FRAME:025221/0747

Effective date: 20101022

Owner name: UNIVERSITY OF WASHINGTON, WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RABINOVITCH, PETER S.;DAI, DAO-FU;REEL/FRAME:025221/0532

Effective date: 20101026

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF WASHINGTON / CENTER FOR COMMERCIALIZATION;REEL/FRAME:033694/0807

Effective date: 20140619